Opus Genetics, Inc. IRD
Regular-session close
After hours · Nov 19, 7:39 PM ET
- YTD
- +102.99%
- 1 year
- +119.35%
5D +0.07 (+1.76%)
- Market cap
- 394.35M
- Revenue (ttm)
- 8.38M
- EPS (ttm)
- -1.48
- Shares out
- 31.57M
- Forward P/E
- -1.20
- YTD return
- +102.99%
- 1-year return
- +119.35%
- 50-day average
- 1.13
- Volume
- 598.16K
- Avg volume
- 2.57M
- Open
- 3.96
- Previous close
- 3.92
- Day's range
- 3.93 – 4.12
- 52-week range
- 1.86 – 7.07
- Analysts
- Strong Buy
- Price target
- 10.50 (+157.4%)
Key statistics
- 200-day average
- 1.52
- Enterprise value
- -5.75M
- Price / sales
- 3.88
- Price / book
- 0.79
- Revenue growth
- -67.60%
- Free cash flow
- -8.28M
- Total cash
- 36.63M
- Return on equity
- -64.30%
- Short % of float
- 2.91%
Fundamental scorecard
5 of 25 checks passed on IRD’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.30 | -0.29 | +0.01 | +3.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 23, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2024 | Canaccord Genuity | main | Buy | Buy |
| May 13, 2024 | Canaccord Genuity | main | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- opusgtx.com
News
Opus Genetics Says Global RDH12 Alliance Commits Up To $1.6M To Advance OPGx-RDH12 Development For RDH12-LCA Treatment
Opus Genetics Doses First Participant In Phase 1/2 Clinical Trial Evaluating Opgx-RDH12, Investigational Gene Therapy For RDH12-LCA, Rare Inherited Retinal Disease
Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness RBC Capital Maintains Outperform on Opus Genetics, Raises Price Target to $11
HC Wainwright & Co. Maintains Buy on Opus Genetics, Raises Price Target to $14
Opus Genetics Q3 EPS $(0.46) Misses $(0.15) Estimate, Sales $1.137M Miss $1.959M Estimate
FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis
Your note
Sign in to keep a note on IRD — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.14% | 992,200 | 1.02M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.86% | 272,281 | 280.45K | Sep 29, 2024 |
| Bridgeway Capital Management, Inc. | 0.53% | 165,751 | 170.72K | Sep 29, 2024 |
| Richmond Brothers, Inc. | 0.49% | 155,620 | 160.29K | Sep 29, 2024 |
| Blackrock Inc. | 0.35% | 109,323 | 112.60K | Sep 29, 2024 |
| Knoll Capital Management, LLC | 0.32% | 100,000 | 103.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.14% | 675,815 | 696.09K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.92% | 288,947 | 297.62K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 142,910 | 147.20K | Oct 30, 2024 |
| Bridgeway Fds Inc-Omni Small Cap Value Fund | 0.25% | 80,400 | 82.81K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.18% | 57,649 | 59.38K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.14% | 44,036 | 45.36K | Sep 29, 2024 |
